Investigating genetic factors in immune-related side effects from cancer immunotherapy
Official title: IL-6 and IL-6R genetic polymorphisms in immune-related adverse events caused by cancer immunotherapy
Funded at University of Colorado Denver · NIH-10997213 · Data updated 2026-11-12
This study is looking at how certain genes might affect the chances of experiencing side effects from cancer immunotherapy, especially for those using immunocheckpoint inhibitors, and it aims to help identify patients who may be at higher risk so that we can find ways to reduce these side effects while still keeping the treatment effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $401,115 |
| NIH project number | 1R21CA287678-01A1 |
| Project ID | NIH-10997213 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients undergoing immunotherapy who may be at risk for immune-related adverse events.
✕Less likely to help
Patients who are not receiving immunotherapy or those with no genetic predisposition to immune-related adverse events may not benefit from this research.
What this research studies
This research focuses on understanding how genetic variations in the IL-6 and IL-6R genes may influence the occurrence of immune-related adverse events (irAEs) in patients receiving cancer immunotherapy, particularly immunocheckpoint inhibitors. By analyzing patient samples, the study aims to identify those at higher risk for these side effects and explore mechanisms that drive these reactions. The goal is to develop strategies to minimize these adverse effects while maintaining the effectiveness of cancer treatments. Patients may be asked to provide genetic samples and health information to support this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment plans that reduce the risk of severe side effects from cancer immunotherapy.
How similar studies have gone: Previous research has shown that genetic factors can influence the occurrence of adverse events in other treatments, suggesting that this approach may yield valuable insights.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Rincon, Mercedes — University of Colorado Denver
- Study coordinator: Rincon, Mercedes
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.